In chronic lymphocytic leukemia (CLL), venetoclax has established itself as one of the most effective monotherapies in certain contexts. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, spoke to us about the biggest updates in CLL being talked about at the conference. These include the MURANO trial (NCT02005471), and other studies investigating the most effective venetoclax combinations, primarily aiming to achieve a deep, durable remission, and only requiring a fixed duration of therapy, rather than indefinite treatment.
Novel venetoclax combination therapy advancing the field of CLL
